A working peptide dosing schedule comes down to three elements: the target dose, how often you inject it, and a titration ladder that moves you from a low starting point to maintenance. Some schedules follow published prescribing information, while others, like BPC-157, rely on experimental, non-standardized use. The reference chart and worked math below walk through both, and clinicians can build and supervise a personalized version of either.
TL;DR:
- Weekly agents start at 0.25 mg for four weeks, then increase in steps held at least four weeks to reduce gastrointestinal side effects.
- BPC-157 has no standardized human dose; animal studies use varied schedules, so online amounts are personal practice, not verified guidance.
- A 10 mg vial mixed with 2 mL yields 5,000 mcg per mL; a 250 mcg dose equals 50 units on a syringe calibrated to 100 units per mL.
- People taking diabetes, thyroid, or hormone medicines, and anyone with kidney or liver disease, should have a clinician review the schedule before starting.
- Most reconstituted peptides need refrigeration and protection from light; never freeze them, and discard any vial that turns cloudy or discolored.
Table of Contents
- At-a-glance dosing reference: frequency categories and starting ranges
- Reconstitution math and syringe-unit conversions
- Example schedules and titration plans for common peptides
- Planning cycles and stacking: what clinicians prioritize
- Dose ranges and administration frequency
- Storage and handling requirements to maintain stability
- Common side effects and how dosing schedules reduce risk
- Contraindications and who should avoid certain peptides
- Adjustments for older adults and those with kidney or liver concerns
- Interactions with other therapies and medications
- Monitoring protocols during peptide therapy
- Our take on building a dosing schedule that actually works
- Get a personalized peptide plan at Vitaluxe
- FAQ
- Sources
At-a-glance dosing reference: frequency categories and starting ranges
Most peptide schedules fall into one of three frequency patterns, and knowing which bucket a compound belongs to tells you most of what you need before you even touch a calculator.
- Daily or multiple-daily: growth hormone secretagogues like Ipamorelin are typically dosed once or twice a day, timed around fasted windows.
- Once-weekly: GLP-1 class agents follow a fixed weekly injection day with scheduled dose increases built into the label.
- Injury or healing, as-needed: compounds associated with tissue repair are sometimes used daily for a defined course rather than indefinitely.
Weekly GLP-1 agents have the clearest paper trail because their schedules come directly from FDA prescribing information, which lays out a starting dose, a fixed escalation calendar, and a maintenance range. That label-based structure is the exception rather than the rule in the peptide space. BPC-157, by contrast, has no FDA-approved human dosing protocol at all. A 2026 PubMed review notes that pilot studies and small cohorts use varying routes, including intraarticular and intravenous administration, but no large-scale human dosing standard exists. Anyone comparing a label-derived schedule to a forum-sourced BPC-157 regimen is comparing two very different categories of evidence, and treating them the same way is where a lot of dosing mistakes start.
Reconstitution math and syringe-unit conversions
Reconstitution is just unit conversion, but it is the step where small errors do the most damage, so it helps to slow down and work it in order.
- Convert the vial strength from milligrams to micrograms (1 mg = 1,000 mcg).
- Divide the total micrograms in the vial by your target dose in micrograms to find doses per vial.
- Decide how much diluent (usually bacteriostatic water) to add, which sets your concentration in mcg per mL.
- Convert that concentration to insulin-syringe units on a U-100 syringe, where 100 units equals 1 mL.
- Draw the exact unit mark that corresponds to your target dose.
Worked example 1: a 10 mg vial holds 10,000 mcg. A 250 mcg target dose means the vial yields 40 doses (10,000 ÷ 250). If you reconstitute with 2 mL of diluent, the concentration is 5,000 mcg per mL, or 50 mcg per 10 units on a U-100 syringe. A 250 mcg dose draws to the 50-unit mark.
Worked example 2: a multi-dose vial intended for weekly dosing, say 5 mg reconstituted with 2.5 mL, gives 2,000 mcg per mL. A weekly 500 mcg dose draws to 25 units, and the vial supports 10 weekly doses before it runs out, which matters for planning refill timing alongside storage limits.
Use bacteriostatic water rather than plain sterile water for multi-dose vials, since it resists bacterial growth across repeated draws. Label every vial with the reconstitution date and concentration, and match your syringe to the dose, since a U-100 insulin syringe is built for small-volume precision that a standard syringe cannot match.
Pro Tip: Write the concentration (mcg per unit) directly on the vial label the moment you reconstitute it, before you forget which dilution you used.
Example schedules and titration plans for common peptides
Titration exists to let your body adjust gradually, and the pacing looks different depending on whether a compound has a regulatory label behind it or not.
- Label-derived weekly pattern: semaglutide-based agents start at 0.25 mg once weekly for four weeks, then step up through 0.5 mg, 1 mg, and higher maintenance doses, holding each step for at least four weeks before the next increase. That four-week hold is specifically designed to limit gastrointestinal side effects.
- CJC-1295 with Ipamorelin: clinic-supervised plans commonly pair a nightly or twice-daily injection with a fasted dosing window, and our clinician-reported timeline for noticeable outcomes runs about 8 to 12 weeks.
- TB-500: often scheduled as a loading phase of more frequent doses for several weeks, tapering to a lower maintenance frequency once initial repair goals are met; research-grade product documentation is sold strictly for laboratory research, not self-administration, which is a meaningful distinction from a clinic-prepared dose.
- BPC-157: this is the clearest example of an evidence gap. Animal studies commonly dose once daily across models lasting anywhere from a single dose to 90 days, and show accelerated tissue healing in those models. None of that translates into an established human dosing standard, and the same PubMed review behind the earlier dosing discussion confirms that human use remains experimental. Anyone encountering a specific "safe" BPC-157 human dose online is reading someone's personal practice, not a verified standard.
The pattern across all four examples is the same: start low, hold at each step long enough to see how your body responds, and treat the maintenance phase as a plateau to be reassessed rather than a permanent setting.
Planning cycles and stacking: what clinicians prioritize
When a plan includes more than one peptide, sequencing matters as much as the individual doses. Growth hormone secretagogues work best in a fasted state, so our practice is to schedule those doses first, typically before bed or first thing in the morning, before any food intake disrupts the response. Healing-focused peptides are more flexible and can usually be fit around the secretagogue schedule rather than the other way around.
A simple 7-day calendar, with each compound's day and time written out in advance, cuts down on missed doses far more reliably than trying to remember a schedule from memory. We set client expectations around an 8 to 12 week timeline for most outcomes, which is also when we revisit labs and adjust the plan. Baseline labs before starting, a check-in partway through, and a clear list of symptoms that warrant an earlier visit are the three guardrails we build into every supervised plan.
Pro Tip: Keep fasted-dependent peptides on one fixed time slot each day; even a two-hour drift can blunt the response you're after.
Dose ranges and administration frequency
Dose ranges vary enormously by peptide class, which is why a single "standard dose" rarely applies across the board. Weekly GLP-1 agents move through a defined range from a 0.25 mg starting dose up to several milligrams at maintenance, with every step specified in the prescribing label. Growth hormone secretagogues tend to use microgram-level doses delivered daily or twice daily, since their action depends more on consistent exposure than on a single large dose.
Injury-focused peptides are often dosed daily during an active healing phase and then tapered or discontinued once the course is complete, rather than continued indefinitely. Frequency and dose size are linked: a compound dosed more often is almost always dosed lower per administration, and a compound dosed weekly is dosed higher per administration to cover the same interval. Matching frequency to the compound's half-life is part of why label-based agents specify an exact weekly day, while daily-use peptides tolerate more flexibility in timing as long as the total daily amount stays consistent.
Storage and handling requirements to maintain stability
Most reconstituted peptides need refrigeration, typically between 36°F and 46°F, and should be kept away from light, since many peptide compounds degrade faster when exposed to direct sunlight or heat. Lyophilized (freeze-dried) peptide powder, before reconstitution, is generally more stable and can often be stored at a cooler or frozen temperature until you are ready to mix it.
Once reconstituted, most peptides are intended to be used within a few weeks, and the exact window depends on the specific compound and diluent choice. Avoid shaking the vial vigorously, since that can damage the peptide structure; swirl gently instead. Never freeze a reconstituted vial, since repeated freeze-thaw cycles break down the peptide chain faster than refrigerated storage. Label each vial with the reconstitution date so you are not guessing later about how long it has been in use, and discard any vial that looks cloudy or discolored, since that can signal contamination or degradation.
Common side effects and how dosing schedules reduce risk
Side effects vary by peptide, but a few patterns repeat often enough to plan around. Weekly GLP-1 agents are associated with gastrointestinal effects, including nausea and digestive upset, especially during dose increases, which is exactly why the FDA-labeled titration schedule holds each dose step for four weeks before escalating. That built-in pause gives your digestive system time to adjust before the next increase.
Growth hormone secretagogues can cause injection-site redness, mild water retention, or temporary flushing, which is one reason clinic-supervised protocols start at a conservative dose rather than a target maintenance dose from day one. Starting low and escalating gradually, rather than jumping straight to a higher dose, is the single most consistent risk-reduction strategy across every peptide category discussed here. Injection-site rotation also matters: using the same spot repeatedly increases the likelihood of local irritation, so most supervised plans rotate between the abdomen, thigh, and upper arm.
Contraindications and who should avoid certain peptides
A peptide dosing schedule should never be built in isolation from your health history. Active cancer, pregnancy, and breastfeeding are generally treated as reasons to avoid growth hormone secretagogues, since stimulating growth hormone and IGF-1 pathways carries theoretical risk in those situations. People with a history of certain hormone-sensitive conditions should discuss any peptide therapy with a physician before starting rather than relying on a generic schedule found online.
For compounds without FDA-approved human dosing, such as BPC-157, the honest answer is that formal contraindication data does not exist in the way it does for an approved drug. That absence of data is itself a reason for caution, not a green light, and it is part of why we start every peptide consultation with a review of medical history and current medications before recommending any schedule.
Adjustments for older adults and those with kidney or liver concerns
Age and organ function change how a body processes and clears nearly every compound, and peptides are no exception. Older adults often start at the lower end of any dose range and are monitored more closely during the early titration period, since metabolic clearance can slow with age.
Kidney or liver impairment is a more significant consideration, because several peptide classes rely on those organs for clearance. FDA labeling for GLP-1 class agents addresses dosing considerations and missed-dose windows that become more relevant when clearance is slower than average. Anyone with diagnosed kidney or liver disease should treat a standard dosing chart as a starting point for a conversation with a clinician, not as a fixed protocol, since the right adjustment depends on the specific condition and its severity.
Interactions with other therapies and medications
Peptide therapy rarely happens in a vacuum, and a few interaction patterns are worth flagging before you build a schedule. GLP-1 class agents can slow gastric emptying, which affects how other oral medications are absorbed, so timing relative to other prescriptions matters more than with a simple supplement. The FDA label for weekly GLP-1 agents specifically addresses missed-dose windows and injection-site rotation, both of which become more important when a reader is also managing insulin or other glucose-lowering drugs.
Growth hormone secretagogues can interact with existing hormone therapies, and stacking multiple peptides without a clear schedule increases the chance that one compound's timing undermines another's. This is where a written weekly calendar earns its keep: it is far easier to spot a conflict on paper than to notice it after a missed or doubled dose. Anyone on prescription medications, particularly for diabetes, thyroid conditions, or hormone replacement, should review a proposed peptide schedule with a clinician before starting rather than layering it on without oversight.
Monitoring protocols during peptide therapy
A dosing schedule is not a one-time decision. Baseline labs before starting give you a reference point, and follow-up labs partway through, often around the same 8 to 12 week window we use to judge clinical outcomes, let you confirm the plan is working as intended rather than guessing from how you feel.
Tracking should include both subjective measures, like sleep quality, energy, or recovery time, and objective ones where relevant, such as relevant hormone panels or kidney and liver function markers for longer courses. Any new or worsening symptom, from persistent injection-site reaction to unexpected fatigue, is a reason to check in before continuing the schedule rather than pushing through it. Readers using experimental peptides like BPC-157 should apply extra caution here, since the lack of standardized human dosing data means there is no established safety baseline to compare against, which puts more weight on close self-monitoring and professional check-ins.
Our take on building a dosing schedule that actually works
Our nurse-led team builds every peptide plan around a client's actual history and goals rather than a generic chart pulled from a label or a forum post. Most of our clients see meaningful change within 8 to 12 weeks, whether the goal is recovery, sleep, or cellular wellness, and that timeline is part of what we discuss at the first visit. A consult makes the most sense once you are stacking more than one peptide or working with a compound that lacks a standardized human dose.
— Debbie
Get a personalized peptide plan at Vitaluxe
Building a dosing schedule from a chart only gets you so far, especially once stacking or an experimental compound enters the picture. Peptide services are part of a broader menu that includes IV therapies, and each peptide plan is built around baseline labs, your health history, and a check-in cadence that matches the 8 to 12 week timeline most clients see results within.
Pricing for peptide services is available on request, and our Essential and Elite membership plans offer a way to fold ongoing peptide follow-ups into recurring visits. Browse our full services menu or reach out through our contact page to start with a consult.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
FAQ
Is 2 mg of peptide each week enough?
It depends entirely on the specific peptide and your target dose, since a 2 mg weekly amount might be well above maintenance for one compound and far below a therapeutic range for another. Compare the total weekly amount against the dose range for your specific peptide, such as the FDA-labeled escalation schedule for weekly GLP-1 agents, rather than treating 2 mg as a universal benchmark.
What are the recommended doses for peptides?
Recommended doses only exist in a formal sense for peptides with FDA-approved labels, such as weekly GLP-1 agents, which specify an exact starting dose and escalation schedule. For peptides without regulatory approval, like BPC-157, no standardized human dose exists, and published literature describes only experimental pilot use rather than a confirmed safe range.
How much peptide should I take per day?
Daily dosing applies mainly to compounds like growth hormone secretagogues or short-course healing peptides, where microgram-level doses are typically split into one or two daily injections. The right daily amount depends on the specific compound, your titration stage, and whether you are in an escalation phase or already at maintenance, which is why a personalized plan outperforms a generic daily figure.
How do I calculate how much peptide I need?
Start by converting the vial strength from milligrams to micrograms, then divide that number by your target dose in micrograms to find how many doses the vial contains. From there, your diluent volume sets the concentration, which converts directly into the syringe units you draw for each dose.
Sources
- PubMed: BPC-157 human/animal studies (2026)
- FDA prescribing information: semaglutide (OZEMPIC/WEGOVY label excerpts)
- PMC review: BPC-157 and healing studies